High mobility group protein 20B (HMG20B)

High mobility group protein 20B (HMG20B) is a structural and regulatory chromatin protein that acts as an integral subunit of chromatin-modifying complexes such as the LSD1–CoREST complex, which mediates histone demethylation and transcriptional repression, influencing chromatin structure and cell-specific gene expression. HMG20B is essential for maintaining normal cell division by interacting directly with BRCA2 at specific BRC repeat motifs, particularly BRC5, to mediate the final steps of cytokinesis; disruptions in this interaction can delay cytokinesis, cause genomic instability, and contribute to tumor development. In hematopoietic and neuronal contexts, HMG20B regulates cell fate and differentiation by modulating chromatin and recruiting or stabilizing other regulators such as LSD1 and GFI1 on chromatin. Its deficiency or malfunction is implicated in tumorigenesis and altered cell fate decisions, notably in cancer and hematopoietic differentiation disorders. Notes: - HMG20B is not commonly referred to as a druggable/therapeutic target (e.g., receptor, enzyme, transporter), but rather as an epigenetic and chromatin regulatory factor. - There are no widely reported small-molecule drugs directly targeting HMG20B, nor established biomarker or patient selection criteria directly reliant on HMG20B status as of the most recent data. - Key risks of targeting or losing HMG20B relate to chromosomal instability and cancer progression.

Other names

BRAF25HMGX2BRAF35HMGXB2SOXLPP7706PP8857SMARCE1RBRCA2-associated factor 35SMARCE1-related protein